Ely Benaim - 06 Jan 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: Chief Medical Officer
Issuer ticker: NVCR
Reported as of: 06 Jan 2023
Net transaction value: +$6,106
SEC form: 4
Accepted by SEC: 10 Jan 2023, 15:14:46 UTC
Prior SEC filing: 04 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Steven Robbins Attorney in Fact for Ely Benaim

Key filing fact

Ely Benaim filed Form 4 for NovoCure Ltd (NVCR) on 10 Jan 2023.

Key facts

This page summarizes Ely Benaim's Form 4 filing for NovoCure Ltd (NVCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jan 2023, 15:14.

Change

Previous filing in this sequence was filed on 04 Aug 2022.
Current net transaction value: +$6,106.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Award

Transaction value: $6,106
Shares: +98
Change %: +0.34%
Price: $62.30
Shares after: 28,770
Date: 06 Jan 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.